-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9

Benzinga·12/09/2025 16:28:50
Listen to the news
Barclays analyst Glen Santangelo initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight rating and announces Price Target of $9.